Transplant Diagnostics

Episode 24 | How Cell and Gene Therapies Can Bankrupt Unprepared Employers

Podcasts, Transplant Diagnostics | Nov 7, 2025
In this episode of Only Healthcare's Risk Series, hosts Michael Navin and Randy Vogenberg welcome Tom Sondergeld to discuss the explosive growth of ultra-high-cost therapies threatening to devastate employer-sponsored health plans.

Episode 23 | Healthcare's Lightning Strike Cost Problem

Podcasts, Prior Authorization & Appeals, Transplant Diagnostics | Nov 1, 2025
In this episode of Only Healthcare's Risk Series, hosts Michael Navin and Randy Vogenberg welcome Drew Wilkins to discuss how cell and gene therapies are fundamentally breaking America's employer-sponsored healthcare system.

Employers Assert Greater Control Over Pharmacy Benefits Amid Rising Treatment Costs

George Padron
Prior Authorization & Appeals, Cost-Effective Analysis, Precision Medicine, Healthcare Headlines, Healthcare Systems & Business, Transplant Diagnostics, Liquid Biopsy & MRD | Oct 10, 2025
Survey finds employers asserting control over pharmacy benefits with just 41% accepting standard formularies and 69% using data to hold vendors accountable.

State Medicaid Program Weighs Coverage Pause for Gene Therapy Amid Safety Concerns

Sonia Reyes
Prior Authorization & Appeals, Healthcare Headlines, Transplant Diagnostics, Liquid Biopsy & MRD | Oct 9, 2025
New York's Drug Utilization Review Board recommends pausing Medicaid coverage of Sarepta's Elevidys gene therapy due to safety concerns and a $45M annual cost.

Payer Challenges Mount as Gene Therapy Companies Retreat

George Padron
Medicare/Medicaid Updates, Precision Medicine, Healthcare Headlines, Transplant Diagnostics, Liquid Biopsy & MRD | Oct 9, 2025
Gene therapy manufacturers step back from blood disorder treatments despite regulatory approval, facing cost barriers and competition from improved transplant methods.